Craniopharyngioma With Tumoral Hemorrhage

Clinical Features and Risk Factors of Craniopharyngioma With Tumoral Hemorrhage

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04937335

Enrollment

185

Registered

2021-06-24

Start date

2013-01-01

Completion date

2021-02-01

Last updated

2021-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apoplexy, Craniopharyngioma

Keywords

craniopharyngioma, endocrine, risk factor, tumoral hemorrhage

Brief summary

Clinical data of 185 consecutive patients receiving resective operation with a pathological diagnosis of craniopharyngioma in our hospital between January 2013 and February 2021 were collected. Among these patients, 18 of them were recognized as craniopharyngioma with tumoral hemorrhage during the operation.

Detailed description

For each case, age, gender, smoking status, alcohol intake, past history, symptoms, blood pressure, blood cell count, blood biochemical tests, coagulation tests, hormone tests, radiological results, surgical treatment and the outcome at discharge were collected. The first test result after admission and before the operation was taken for the items of blood tests with multiple times in the analysis.

Interventions

OTHERintratumoral hemorrhage

Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* receive resective operation with a pathological diagnosis of craniopharyngioma in our hospital * enter our hospital between January 2013 and February 2021

Exclusion criteria

* have a non-craniopharyngioma or unverified pathological diagnosis at discharge * have received surgical or radiological treatment on the sellar region * receive treatment of coagulation modulation, immunosuppressive agents or chemotherapeutic drugs * combine with other clinical emergencies including acute myocardial infarction, cerebral stroke, trauma and sepsis at admission * have been diagnosed with other tumors, hematological diseases, autoimmune diseases, liver failure or renal failure

Design outcomes

Primary

Measure	Time frame	Description
craniopharyngioma with tumoral hemorrhage	during the operation	Current study is a case-control study whose primary outcome is tumoral hemorrhage observed during the operation, which devided the craniopharyngioma patients into hemorrhage group and non-hemorrhage group.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026